Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HRrEF) discharge medication prescribing

Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?

Amy Richardson, Elizabeth Tolley, Jonathan Hartmann, Jasmine Reedus, Brandi Bowlin, Christopher Finch, Christopher W. Sands, Timothy Self

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge. CHF coexists in more than 20% of patients with COPD, and is associated with early readmission for COPD. Reducing 30-day hospital readmissions for COPD is of intense current interest. Methodology A retrospective chart review was performed to identify patients discharged with COPD exacerbation and HFrEF. The primary objective was to evaluate if discharge medication prescribing following guidelines for both COPD and HFrEF correlates with reduced 30-day readmission rates. Results The study included 281 admissions with 39.1% prescribed appropriate discharge medications for both COPD and HFrEF; 30-day readmission rate was 24.5% for these patients compared to 31.1% that were not prescribed appropriate medications (p = 0.24). Beta blockers, ACE inhibitors or ARBS, and aldosterone antagonists were under-prescribed, but this did not significantly associate with increased readmission (p = 0.51, p = 0.23 or 0.99, and p = 0.18, respectively). Those prescribed hydralazine or nitrates were more likely to readmit (both p = 0.01). Diabetes and hyperlipidemia were associated with increased readmission (p = 0.01 and 0.05). Conclusions This study did not show a significant difference in 30-day readmission rate based on appropriate discharge medications for both COPD and HFrEF. The comorbidities diabetes and hyperlipidemia and prescription of hydralazine or nitrates were significantly associated with increased readmission rate. Larger patient populations may be needed to assess if guideline based discharge medication prescribing is associated with reduced 30-day readmissions for COPD.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalRespiratory Medicine
Volume119
DOIs
StatePublished - Oct 1 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Heart Failure
Guidelines
Drug Therapy
Hydralazine
Hyperlipidemias
Nitrates
Mineralocorticoid Receptor Antagonists
Patient Readmission
Angiotensin-Converting Enzyme Inhibitors
Prescriptions
Disease Progression
Comorbidity
Population

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HRrEF) discharge medication prescribing : Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? / Richardson, Amy; Tolley, Elizabeth; Hartmann, Jonathan; Reedus, Jasmine; Bowlin, Brandi; Finch, Christopher; Sands, Christopher W.; Self, Timothy.

In: Respiratory Medicine, Vol. 119, 01.10.2016, p. 135-140.

Research output: Contribution to journalArticle

@article{6ea3cc78fd514aafaf507ee73b5d691c,
title = "Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HRrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?",
abstract = "Introduction Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge. CHF coexists in more than 20{\%} of patients with COPD, and is associated with early readmission for COPD. Reducing 30-day hospital readmissions for COPD is of intense current interest. Methodology A retrospective chart review was performed to identify patients discharged with COPD exacerbation and HFrEF. The primary objective was to evaluate if discharge medication prescribing following guidelines for both COPD and HFrEF correlates with reduced 30-day readmission rates. Results The study included 281 admissions with 39.1{\%} prescribed appropriate discharge medications for both COPD and HFrEF; 30-day readmission rate was 24.5{\%} for these patients compared to 31.1{\%} that were not prescribed appropriate medications (p = 0.24). Beta blockers, ACE inhibitors or ARBS, and aldosterone antagonists were under-prescribed, but this did not significantly associate with increased readmission (p = 0.51, p = 0.23 or 0.99, and p = 0.18, respectively). Those prescribed hydralazine or nitrates were more likely to readmit (both p = 0.01). Diabetes and hyperlipidemia were associated with increased readmission (p = 0.01 and 0.05). Conclusions This study did not show a significant difference in 30-day readmission rate based on appropriate discharge medications for both COPD and HFrEF. The comorbidities diabetes and hyperlipidemia and prescription of hydralazine or nitrates were significantly associated with increased readmission rate. Larger patient populations may be needed to assess if guideline based discharge medication prescribing is associated with reduced 30-day readmissions for COPD.",
author = "Amy Richardson and Elizabeth Tolley and Jonathan Hartmann and Jasmine Reedus and Brandi Bowlin and Christopher Finch and Sands, {Christopher W.} and Timothy Self",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.rmed.2016.09.008",
language = "English (US)",
volume = "119",
pages = "135--140",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HRrEF) discharge medication prescribing

T2 - Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?

AU - Richardson, Amy

AU - Tolley, Elizabeth

AU - Hartmann, Jonathan

AU - Reedus, Jasmine

AU - Bowlin, Brandi

AU - Finch, Christopher

AU - Sands, Christopher W.

AU - Self, Timothy

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge. CHF coexists in more than 20% of patients with COPD, and is associated with early readmission for COPD. Reducing 30-day hospital readmissions for COPD is of intense current interest. Methodology A retrospective chart review was performed to identify patients discharged with COPD exacerbation and HFrEF. The primary objective was to evaluate if discharge medication prescribing following guidelines for both COPD and HFrEF correlates with reduced 30-day readmission rates. Results The study included 281 admissions with 39.1% prescribed appropriate discharge medications for both COPD and HFrEF; 30-day readmission rate was 24.5% for these patients compared to 31.1% that were not prescribed appropriate medications (p = 0.24). Beta blockers, ACE inhibitors or ARBS, and aldosterone antagonists were under-prescribed, but this did not significantly associate with increased readmission (p = 0.51, p = 0.23 or 0.99, and p = 0.18, respectively). Those prescribed hydralazine or nitrates were more likely to readmit (both p = 0.01). Diabetes and hyperlipidemia were associated with increased readmission (p = 0.01 and 0.05). Conclusions This study did not show a significant difference in 30-day readmission rate based on appropriate discharge medications for both COPD and HFrEF. The comorbidities diabetes and hyperlipidemia and prescription of hydralazine or nitrates were significantly associated with increased readmission rate. Larger patient populations may be needed to assess if guideline based discharge medication prescribing is associated with reduced 30-day readmissions for COPD.

AB - Introduction Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge. CHF coexists in more than 20% of patients with COPD, and is associated with early readmission for COPD. Reducing 30-day hospital readmissions for COPD is of intense current interest. Methodology A retrospective chart review was performed to identify patients discharged with COPD exacerbation and HFrEF. The primary objective was to evaluate if discharge medication prescribing following guidelines for both COPD and HFrEF correlates with reduced 30-day readmission rates. Results The study included 281 admissions with 39.1% prescribed appropriate discharge medications for both COPD and HFrEF; 30-day readmission rate was 24.5% for these patients compared to 31.1% that were not prescribed appropriate medications (p = 0.24). Beta blockers, ACE inhibitors or ARBS, and aldosterone antagonists were under-prescribed, but this did not significantly associate with increased readmission (p = 0.51, p = 0.23 or 0.99, and p = 0.18, respectively). Those prescribed hydralazine or nitrates were more likely to readmit (both p = 0.01). Diabetes and hyperlipidemia were associated with increased readmission (p = 0.01 and 0.05). Conclusions This study did not show a significant difference in 30-day readmission rate based on appropriate discharge medications for both COPD and HFrEF. The comorbidities diabetes and hyperlipidemia and prescription of hydralazine or nitrates were significantly associated with increased readmission rate. Larger patient populations may be needed to assess if guideline based discharge medication prescribing is associated with reduced 30-day readmissions for COPD.

UR - http://www.scopus.com/inward/record.url?scp=84986536261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986536261&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2016.09.008

DO - 10.1016/j.rmed.2016.09.008

M3 - Article

VL - 119

SP - 135

EP - 140

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -